Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 35365302)

  • 1. Cost-Effectiveness of Tumor Genomic Profiling to Guide First-Line Targeted Therapy Selection in Patients With Metastatic Lung Adenocarcinoma.
    Dong OM; Poonnen PJ; Winski D; Reed SD; Vashistha V; Bates J; Kelley MJ; Voora D
    Value Health; 2022 Apr; 25(4):582-594. PubMed ID: 35365302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials.
    Suh JH; Johnson A; Albacker L; Wang K; Chmielecki J; Frampton G; Gay L; Elvin JA; Vergilio JA; Ali S; Miller VA; Stephens PJ; Ross JS
    Oncologist; 2016 Jun; 21(6):684-91. PubMed ID: 27151654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modeling Costs and Life-Years Gained by Population-Wide Next-Generation Sequencing or Single-Gene Testing in Nonsquamous Non-Small-Cell Lung Cancer in the United States.
    Lemmon CA; Zhou J; Hobbs B; Pennell NA
    JCO Precis Oncol; 2023 Jan; 7():e2200294. PubMed ID: 36634300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness of Comprehensive Genomic Profiling in Patients With Non-Small Cell Lung Cancer for the Colombian Health System.
    Gamboa O; Bonilla CE; Quitian D; Torres GF; Buitrago G; Cardona AF
    Value Health Reg Issues; 2024 Jan; 39():115-125. PubMed ID: 38101152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive genomic profiling in advanced/metastatic colorectal cancer: number needed to test and budget impact of expanded first line use.
    Proudman D; DeVito NC; Belinson S; Allo MA; Morris ED; Signorovitch J; Patel AK
    J Med Econ; 2022; 25(1):817-825. PubMed ID: 35593483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantifying the Value of Multigene Testing in Resected Early Stage Lung Adenocarcinoma.
    Muthusamy B; Raskina K; Lofgren KT; Li G; Tolba K; Schwed K; Castellanos E; Huang RSP; Oxnard GR; Schrock AB; Pennell N
    J Thorac Oncol; 2023 Apr; 18(4):476-486. PubMed ID: 36494074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of first-line treatment with crizotinib in ROS1-rearranged advanced non-small cell lung cancer (NSCLC) in Canada.
    Beca JM; Walsh S; Raza K; Hubay S; Robinson A; Mow E; Keech J; Chan KKW
    BMC Cancer; 2021 Oct; 21(1):1162. PubMed ID: 34715804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Timely Comprehensive Genomic Profiling With Precision Oncology Treatment Use and Patient Outcomes in Advanced Non-Small-Cell Lung Cancer.
    Yorio J; Lofgren KT; Lee JK; Tolba K; Oxnard GR; Schrock AB; Huang RSP; Brisbin L
    JCO Precis Oncol; 2024 Mar; 8():e2300292. PubMed ID: 38452312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of ceritinib in previously untreated anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer in the United States.
    Zhou ZY; Mutebi A; Han S; Bensimon AG; Louise Ricculli M; Xie J; Dalal A; Culver K
    J Med Econ; 2018 Jun; 21(6):577-586. PubMed ID: 29458286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Total cost of testing for genomic alterations associated with next-generation sequencing versus polymerase chain reaction testing strategies among patients with metastatic non-small cell lung cancer.
    Vanderpoel J; Stevens AL; Emond B; Lafeuille MH; Hilts A; Lefebvre P; Morrison L
    J Med Econ; 2022; 25(1):457-468. PubMed ID: 35289703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
    Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
    Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative.
    Lim SM; Kim EY; Kim HR; Ali SM; Greenbowe JR; Shim HS; Chang H; Lim S; Paik S; Cho BC
    Oncotarget; 2016 Apr; 7(17):24172-8. PubMed ID: 26992220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and economic impact of 'ROS1-testing' strategy compared to a 'no-ROS1-testing' strategy in advanced NSCLC in Spain.
    Rojo F; Conde E; Torres H; Cabezón-Gutiérrez L; Bautista D; Ramos I; Carcedo D; Arrabal N; García JF; Galán R; Nadal E
    BMC Cancer; 2022 Mar; 22(1):292. PubMed ID: 35303812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-Line Durvalumab in Addition to Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer: A U.S.-Based Cost-Effectiveness Analysis.
    Lin S; Luo S; Gu D; Li M; Rao X; Wang C; Huang P; Xu X; Weng X
    Oncologist; 2021 Nov; 26(11):e2013-e2020. PubMed ID: 34431578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ASPiRATION: Australian observational cohort study of comprehensive genomic profiling in metastatic lung cancer tissue.
    Mersiades AJ; Solomon BJ; Thomas DM; Lee CK; Cummins MM; Sebastian L; Ballinger ML; Collignon E; Turnbull OM; Yip S; Morton RL; Brown C; Wheeler PJ; Itchins M; Simes RJ; Pavlakis N
    Future Oncol; 2024 Mar; 20(7):361-371. PubMed ID: 37767626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness of Tepotinib Versus Capmatinib for the Treatment of Adult Patients With Metastatic Non-Small Cell Lung Cancer Harboring Mesenchymal-Epithelial Transition Exon 14 Skipping.
    Yang M; Vioix H; Sachdev R; Stargardter M; Tosh J; Pfeiffer BM; Paik PK
    Value Health; 2023 Apr; 26(4):487-497. PubMed ID: 36503033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness of personalized therapy for first-line treatment of stage IV and recurrent incurable adenocarcinoma of the lung.
    Handorf EA; McElligott S; Vachani A; Langer CJ; Bristol Demeter M; Armstrong K; Asch DA
    J Oncol Pract; 2012 Sep; 8(5):267-74. PubMed ID: 23277762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.
    Ting J; Tien Ho P; Xiang P; Sugay A; Abdel-Sattar M; Wilson L
    Value Health; 2015 Sep; 18(6):774-82. PubMed ID: 26409604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of precision medicine in the fourth-line treatment of metastatic lung adenocarcinoma: An early decision analytic model of multiplex targeted sequencing.
    Doble B; John T; Thomas D; Fellowes A; Fox S; Lorgelly P
    Lung Cancer; 2017 May; 107():22-35. PubMed ID: 27316470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
    Shea M; Costa DB; Rangachari D
    Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.